

Genetics in Medicine

An Official Journal of the ACMG

Date of Release: January 1, 2023

Expiration Date: December 31, 2023

Credits offered: 15 CME

Estimate time of completion: 3 hours per review and up to 15 credits per calendar year.

Course must be completed by the expiration date

Genetics in Medicine's Manuscript Reviewer Continuing Medical Education (CME)/Continuing Education (CE) Guidelines

Thank you for agreeing to provide a review for *Genetics in Medicine (GIM)*. We owe the success of the journal to our reviewers - clinicians, scientists, and scholars who take time out of their busy schedules to carefully read and critique manuscripts contributing to the integrity and quality of scholarly publications. Please refer to *GIM's* guidelines and policies below on eligibility to receive CME/CE credit for peer review of a manuscript under consideration with the journal.

Target Audience

Genetics in Medicine reviewers

Learning Objectives

Participating in the review process may lead the reviewer to identify gaps in knowledge of their field, learn new skills, or reinforce existing expertise in their practice in order to complete the review process effectively.

At the conclusion of a review, participants should be able to:

1. Analyze the manuscript and understand and communicate its strengths and weaknesses
2. Summarize the quality and applicability of the manuscript to the field of medical genetics and genomics
3. Describe the impact of the manuscript on their own practice and/or research

Accredited Continuing Education Information:

Continuing Medical Education (CME AMA & CME Other)

Accreditation

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation (3 hours per review and up to 15 credits per calendar year)

The American College of Medical Genetics and Genomics designates this manuscript review activity for a maximum of 15 *AMA PRA Category 1 Credits™*. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

When submitting your review to *GIM*, click “**YES**” if you would like to receive CME/CE credit for your review. You will be awarded CME/CE credit if your review meets the following requirements:

1. Submitted in a timely manner
2. Identifies the strengths and weaknesses of the manuscript
3. Communicates review feedback effectively to the editors

You will receive an invitation code to enroll in the course. After successful enrollment you may complete the self-report form and claim credits.

FINANCIAL DISCLOSURES

GIM follows the [COPE Ethical Guidelines for Peer Reviewers](#). To maintain the integrity of peer review, reviewers should not review a manuscript for the journal if they do not think that they are competent to assess the research described, they believe there is a conflict of interest that might bias their assessment of the manuscript, or there is any other situation that could bias their review. Reviewers should refer to *GIM*'s policy on [potential conflicts](#) prior to agreeing to act as a reviewer for the journal.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.

**Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*

[ACMG Education Policies](#)

Please review the policies below regarding the ACMG Education program

- [Financial Disclosures and Mitigation Procedure](#)
- [ACMG Content Validation Policy](#)
- [ACMG Content Branding Policy](#)

ACMG Education
acmgeducation.net

Financial Disclosure
& Mitigation



All of the relevant financial relationships listed for these individuals have been mitigated.

Name	Reviewers	Financial Disclosure Relationship/Company
AlKuraya, Fowzan	X	SAB, Equity options: Neutrolis.
Brothers, Kyle	X	Nothing to disclose

Name	Reviewers	Financial Disclosure Relationship/Company
Cho, Mildred	X	Nothing to disclose
Duque-Lasio, Maria Laura	X	Nothing to disclose
Freeman, Peter	X	Nothing to disclose
Higgins, Jan	X	Nothing to disclose
Klugman, Susan	X	Nothing to disclose
Koeberl, Dwight	X	Stock: Asklepios BioPharmaceutical (AskBio) Consultant: Moderna; DSMB: Baxalta
Kozel, Beth	X	Nothing to disclose
Levy-Lahad, Ephrat	X	Nothing to disclose
Manickam, Murugu	X	Nothing to disclose
Miller, David	X	Honoraria: Ambry Genetics Corp.
Mvundura, Mercy	X	Nothing to disclose
Nathanson, Kate	X	Equity Options: Nest Genomics.
Phillips, Kathryn	X	Consultant: Illumina, Inc.
Porath, Binu	X	Nothing to disclose
Rasmussen, Sonja	X	Consultant: Biohaven Pharmaceuticals, f. Hoffmann-La Roche, Teva Pharmaceuticals
Rehder, Catherine	X	Consultant: Alexion Pharmaceuticals, Amicus Therapeutics, Inc.
Rose, Nancy	X	Nothing to disclose
Scheuner, Maren	X	Nothing to disclose
Schrodi, Steve	X	Patents issued and pending assignee Celera Corporation
Shankar, Suma	X	Honoraria: Genzyme Corp.
Steiner, Bob	X	Consultant: Acer Therapeutics, Leadiant Biosciences, Inc., PTC Therapeutics, Inc., Teladoc, Travere Therapeutics, Inc. DSMB: Aeglea BioTherapeutics

Name	Reviewers	Financial Disclosure Relationship/Company
		Employment: PreventionGenetics, a subsidiary of Exact Sciences Grant / Contract: Alexion Pharmaceuticals, Inc.
Stevenson, Dave	X	SAB: Alexion Pharmaceuticals, Novartis
Stewart, Douglas	X	Nothing to disclose
Sutton, V. Reid	X	Stock: Aceragen Consultant: Applied Therapeutics Grant/Contract: Ultragenyx Pharmaceutical, Inc.
Weck, Karen	X	Nothing to disclose
Wu, Ryanne	X	Nothing to disclose
Yin, Xianyong	X	Nothing to disclose

Disclaimer

ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net